173312-36-2

Basic information

• Product Name: 4-Bromo-5-methoxy-2-nitroaniline
• Synonyms: 4-Bromo-5-methoxy-2-nitroaniline;4-bromo-5-methoxy-2-nitrobenzeneamine
• CAS NO: 173312-36-2
• Molecular Formula: C₇H₇BrN₂O₃
• Molecular Weight: 247.04608
• Mol File: 173312-36-2.mol

Chemical Properties

• Boiling Point: 368.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.718±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: -1.44±0.25(Predicted)
• CAS DataBase Reference: 4-Bromo-5-methoxy-2-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-5-methoxy-2-nitroaniline(173312-36-2)
• EPA Substance Registry System: 4-Bromo-5-methoxy-2-nitroaniline(173312-36-2)

Safety Data

• Hazardous Substances Data: 173312-36-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-5-methoxy-2-nitroaniline is used as an intermediate in the synthesis of novel benzimidazoles urea. These benzimidazoles act as inhibitors of DNA Gyrase and Topoisomerase IV, which are essential enzymes in bacterial DNA replication. The inhibition of these enzymes by benzimidazoles leads to potent antibacterial activity, making them valuable in the development of new antibiotics to combat drug-resistant bacterial infections.
Used in Chemical Synthesis:
In the chemical industry, 4-Bromo-5-methoxy-2-nitroaniline is utilized as a building block for the creation of various complex organic molecules. Its unique functional groups allow for further chemical reactions and modifications, enabling the synthesis of a wide range of compounds with diverse applications, such as dyes, pigments, and other specialty chemicals.

Upstream product

• 16133-49-6 5-methoxy-2-nitroaniline 
• 1635-61-6 5-chloro-2-nitroaniline 
• 19056-40-7 4-bromo-3-methoxyaniline 
• 77337-82-7 1-bromo-2-methoxy-4-nitrobenzene 
• 588-16-9 m-methoxyacetanilide 
• 536-90-3 m-Anisidine 
• 20628-18-6 1-acetamido-5-methoxy-2nitrobenzene 
• 173312-35-1 4'-bromo-5'-methoxy-2'-nitroacetanilide 
• 172535-87-4 N-(4-bromo-5-methoxy-2-nitrophenyl)-2,2,2-trifluoroacetamide 

Downstream Products

• 755035-09-7 methyl 2-[(4-bromo-5-methoxy-2-nitrophenyl)amino]-4-chlorobenzoate 
• 1361021-27-3 N-boc-5-bromo-2-iodo-4-methoxyaniline 
• 1361021-29-5 3-tert-butyl-2-hydroxy-5-(6-methoxy-2-oxo-3,4-dipentyl-1,2-dihydroquinolin-7-yl)benzaldehyde 
• 1361021-30-8 3-tert-butyl-2-hydroxy-5-(6-hydroxy-2-oxo-3,4-dipentyl-1,2-dihydroquinolin-7-yl)benzaldehyde 
• 1361021-31-9 N,N'-bis[3-tert-butyl-(6,6'-dihydroxy-3,4-dipentyl-2-oxo-1,2-dihydroquinolin-7yl)salicylidene](1R,2R)diphenyl-1,2-diaminoethane 
• 172535-87-4 N-(4-bromo-5-methoxy-2-nitrophenyl)-2,2,2-trifluoroacetamide 
• 1008361-65-6 5-bromo-6-methoxy-1H-benzo[d]imidazole 
• 108447-01-4 4-bromo-5-methoxy-1,2-phenylenediamine 
• 1052686-65-3 5-methoxy-4-(pyridin-3-yl)-2-nitroaniline 
• 869586-25-4 6-bromo-5-methoxy-3-{2-[methylsulfanyloxymethoxy-(2-nitrobenzenesulfonyl)-amino]ethyl}-indole-1-carboxylic acid tert-butyl ester 
• 869586-05-0 N-(5-bromo-2-iodo-4-methoxyphenyl)-N-[4-(tert-butyldimethylsilanyloxy)but-2-enyl]-2,2,2-trifluoroacetamide 
• 869586-56-1 N-[2-(6-bromo-5-methoxy-1H-indol-3-yl)ethyl]-N-methylsulfanyloxymethoxy-2-nitrobenzenesulfonamide 
• 869585-95-5 N-(5-bromo-2-iodo-4-methoxyphenyl)-2,2,2-trifluoroacetamide 
• 1361021-39-7 1-bromo-4-iodo-2-methoxy-5-nitrobenzene 

Relevant articles and documents

COMBINATION THERAPY

The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. Formula (I). In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION

The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, n and p are as defined herein

Heterocyclic compound used as MNK inhibitor

The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.

HETEROCYCLIC KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Conformationally restricted dynamic supramolecular catalysts for substrate-selective epoxidations

A second generation of a substrate-selective dynamic supramolecular catalytic system consisting of a catalyst part and a receptor part, connected by a hydrogen-bonding motif, has been realized based on rational design. The results from analyses of the equilibrium mixture of the species generated by the components of the first generation system led us to selectively lock the cisoid conformation of the catalyst part to increase the amount of the substrate-selective catalytic cavity in the equilibrium mixture. This was realized by strapping the catalyst part by organic synthesis. This strapping led to an increase in substrate selectivity in the pair-wise competitive epoxidations of pyridyl- vs. phenyl-appended styrenes and pyridyl- vs. phenyl-appended stilbenes of both Z- and E- configuration compared to the first generation system, reaching 3.4:1 as the highest substrate selectivity for Z-mono-pyridyl-stilbene (27a) vs. the corresponding all-carbon analogue (28a) and for E-dipyridyl-stilbene (26b) vs. the corresponding all-carbon analogue (28b), respectively.

Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors

The synthesis and structure-activity relationships (SAR) of Chk1 inhibitors based on a 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one core are described. Specifically, an exploration of the 7 and 8 positions on this previously disclosed core afforded compounds with improved enzymatic and cellular potency.

Benzotriazine inhibitors of kinases

The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.